drugset / Trial / NCT02064491
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-12-31
- Completion
- 2017-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |